300 related articles for article (PubMed ID: 11019977)
1. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood.
Furman MI; Krueger LA; Frelinger AL; Barnard MR; Mascelli MA; Nakada MT; Michelson AD
Thromb Haemost; 2000 Sep; 84(3):492-8. PubMed ID: 11019977
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes.
Li Y; Spencer FA; Ball S; Becker RC
J Thromb Thrombolysis; 2000 Aug; 10(1):69-76. PubMed ID: 10947916
[TBL] [Abstract][Full Text] [Related]
3. Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba.
Pontiggia L; Steiner B; Ulrichts H; Deckmyn H; Forestier M; Beer JH
Thromb Haemost; 2006 Dec; 96(6):774-80. PubMed ID: 17139372
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects.
Klinkhardt U; Graff J; Westrup D; Kirchmaier CM; Esslinger HU; Breddin HK; Harder S
Br J Clin Pharmacol; 2001 Sep; 52(3):297-305. PubMed ID: 11560562
[TBL] [Abstract][Full Text] [Related]
5. Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention.
Day JR; Malik IS; Weerasinghe A; Poullis M; Nadra I; Haskard DO; Taylor KM; Landis RC
Heart; 2004 Jul; 90(7):794-9. PubMed ID: 15201252
[TBL] [Abstract][Full Text] [Related]
6. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
Judge HM; Buckland RJ; Holgate CE; Storey RF
Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
[TBL] [Abstract][Full Text] [Related]
7. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
Marciniak SJ; Jordan RE; Mascelli MA
Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
[TBL] [Abstract][Full Text] [Related]
8. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.
Mousa SA; Bozarth JM; Forsythe MS; Slee A
Cardiovasc Res; 2000 Sep; 47(4):819-26. PubMed ID: 10974231
[TBL] [Abstract][Full Text] [Related]
9. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.
Berny-Lang MA; Jakubowski JA; Sugidachi A; Barnard MR; Michelson AD; Frelinger AL
J Am Heart Assoc; 2013 May; 2(3):e000026. PubMed ID: 23676293
[TBL] [Abstract][Full Text] [Related]
10. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
11. Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro.
Hamilton SF; Miller MW; Thompson CA; Dale GL
J Lab Clin Med; 2004 May; 143(5):320-6. PubMed ID: 15122176
[TBL] [Abstract][Full Text] [Related]
12. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
Ilveskero S; Lassila R
Thromb Res; 2006; 117(3):291-7. PubMed ID: 15878612
[TBL] [Abstract][Full Text] [Related]
13. Stimulated Glanzmann's thrombasthenia platelets produced microvesicles. Microvesiculation correlates better to exposure of procoagulant surface than to activation of GPIIb-IIIa.
Holme PA; Solum NO; Brosstad F; Egberg N; Lindahl TL
Thromb Haemost; 1995 Dec; 74(6):1533-40. PubMed ID: 8772233
[TBL] [Abstract][Full Text] [Related]
14. Greater inhibition of platelet procoagulant activity by antibody-derived glycoprotein IIb--IIIa inhibitors than by peptide and peptidomimetic inhibitors.
Lages B; Weiss HJ
Br J Haematol; 2001 Apr; 113(1):65-71. PubMed ID: 11328283
[TBL] [Abstract][Full Text] [Related]
15. Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity.
Goto S; Tamura N; Li M; Handa M; Ikeda Y; Handa S; Ruggeri ZM
J Thromb Haemost; 2003 Sep; 1(9):2022-30. PubMed ID: 12941046
[TBL] [Abstract][Full Text] [Related]
16. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
[TBL] [Abstract][Full Text] [Related]
17. Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates.
Nakada MT; Sassoli PM; Tam SH; Nedelman MA; Jordan RE; Kereiakes DJ
J Thromb Thrombolysis; 2002 Aug; 14(1):15-24. PubMed ID: 12652146
[TBL] [Abstract][Full Text] [Related]
18. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.
Moser M; Bertram U; Peter K; Bode C; Ruef J
J Cardiovasc Pharmacol; 2003 Apr; 41(4):586-92. PubMed ID: 12658060
[TBL] [Abstract][Full Text] [Related]
19. Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity.
Pedicord DL; Thomas BE; Mousa SA; Dicker IB
Thromb Res; 1998 Jun; 90(6):247-58. PubMed ID: 9700855
[TBL] [Abstract][Full Text] [Related]
20. [Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa inhibitors].
Schrör K
Herz; 2001 Apr; 26 Suppl 1():30-5. PubMed ID: 11349624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]